(a) What are organophosphate compounds? Discuss briefly the clinical features, treatment and postmortem findings of a case of organophosphate poisoning. (15 marks)
(b) (i) Enumerate four differentiating features between benign and malignant tumours.

Question

(a) What are organophosphate compounds? Discuss briefly the clinical features, treatment and postmortem findings of a case of organophosphate poisoning. (15 marks)
(b) (i) Enumerate four differentiating features between benign and malignant tumours. Describe in brief the pathogenesis of cancer cervix. (10 marks)
(ii) Describe in brief the pathogenesis of type I diabetes mellitus. Enumerate two important glomerular lesions of diabetic nephropathy. (10 marks)
(c) (i) Discuss the second line drugs used for the treatment of tuberculosis. (10 marks)
(ii) Discuss the role of aldosterone antagonists as vasodilators. (5 marks)

UPSC Answer Check · Accepted Answer

The directive 'discuss' demands comprehensive coverage with critical analysis across all sub-parts. Allocate approximately 30% time/words to part (a) as it carries 15 marks; 20% each to (b)(i) and (b)(ii) at 10 marks each; 20% to (c)(i); and 10% to (c)(ii). Structure with clear sub-headings for each part, begin with definitions where asked, and ensure clinical-pathological correlations are explicitly stated rather than merely listed.
- (a) Organophosphates: definition as acetylcholinesterase inhibitors; clinical triad of muscarinic, nicotinic and CNS effects; specific antidotes atropine and pralidoxime; postmortem findings including garlic odour, frothy fluid, and constricted pupils
- (b)(i) Benign vs malignant: encapsulation vs invasion, differentiation, mitotic activity, and metastasis; cervical cancer pathogenesis: HPV 16/18 → E6/E7 oncoproteins → p53/Rb inactivation → CIN progression → invasive carcinoma
- (b)(ii) Type I DM pathogenesis: autoimmune destruction of beta cells (HLA-DR3/DR4 association), role of GAD65 and IA-2 antibodies; diabetic nephropathy lesions: diffuse glomerulosclerosis and nodular (Kimmelstiel-Wilson) glomerulosclerosis
- (c)(i) Second-line TB drugs: fluoroquinolones (levofloxacin, moxifloxacin), injectable agents (amikacin, capreomycin), oral bacteriostatics (ethionamide, cycloserine, PAS), and their use in MDR-TB regimens under DOTS-Plus
- (c)(ii) Aldosterone antagonists: spironolactone and eplerenone as competitive antagonists at mineralocorticoid receptors; vasodilatory mechanism via reduced vascular smooth muscle tone and endothelial dysfunction improvement in heart failure

Dimension	Weight	Max marks	Excellent	Average	Poor
Concept correctness	20%	10	Precise definitions of organophosphates as irreversible AChE inhibitors; accurate molecular mechanisms for HPV oncogenesis (E6-p53, E7-Rb), autoimmune beta-cell destruction in T1DM, and mineralocorticoid receptor antagonism; no confusion between first and second-line TB drugs	Broadly correct definitions with minor errors in mechanism (e.g., reversible vs irreversible inhibition, vague HPV mechanism); some mixing of drug categories in TB section	Fundamental errors such as confusing organophosphates with carbamates, stating T1DM is insulin-resistant, or listing first-line drugs (RHEZ) as second-line agents
Clinical correlation	20%	10	Explicit clinical-pathological links: SLUDGE symptoms tied to AChE inhibition; cervical screening via Pap smear and HPV vaccination relevance; diabetic nephropathy progression from microalbuminuria to ESRD; MDR-TB programmatic management under RNTCP in India	Lists clinical features without mechanistic explanation; mentions screening/vaccination superficially; states nephropathy occurs without staging; generic TB mention without Indian context	Isolated facts without clinical integration; no mention of RNTCP/DOTS-Plus for MDR-TB; fails to connect T1DM autoantibodies to clinical presentation
Diagram / pathway	20%	10	Clear diagram of cholinergic synapse showing AChE inhibition by organophosphates; HPV oncogenesis pathway diagram; autoimmune destruction timeline in T1DM; or well-structured flowchart of MDR-TB regimen construction	Mentions diagrams but describes textually without visual clarity; partial pathways with missing steps (e.g., HPV to cancer without intermediate CIN stages)	No attempt at diagrammatic representation where clearly indicated; disorganized presentation of multi-step processes
Differential / staging	20%	10	Clear four-point differentiation of benign vs malignant with pathological basis; FIGO staging or Bethesda system mention for cervical lesions; distinct classification of diabetic nephropathy stages; categorization of second-line TB drugs by group (WHO Group 2-5)	Lists differences without pathological rationale; mentions staging systems superficially; groups TB drugs without WHO classification	No structured comparison; confuses staging systems (e.g., TNM vs FIGO); fails to categorize TB drugs systematically
Management / public-health angle	20%	10	Comprehensive management: atropine dosing with endpoints, pralidoxime reactivation; HPV vaccination (Gardasil/Cervarix) and screening under NPCDCS; insulin regimen principles for T1DM; MDR-TB shorter regimen and injection-free options under Ni-kshay; spironolactone in HFrEF per Indian guidelines	Lists treatments without dosing or monitoring; mentions vaccines without programme context; generic diabetes management without T1DM specificity; standard MDR-TB drugs without regimen construction	Omission of specific antidotes for OP poisoning; no public health context; fails to mention insulin for T1DM; omits programmatic aspects of TB control

Q7

Directive word: Discuss

How this answer will be evaluated

Approach

Key points expected

Evaluation rubric

Practice this exact question

More from Medical Science 2022 Paper I